Tag: ATI-0918
April 30, 2018
Cytori Provides Update on US Manufacturing and EU Approval Plans for ATI-0918, Liposomal Doxorubicin
Cytori Therapeutics (Nasdaq:CYTX) provided an update on its plans for US manufacturing and EU approval for its ATI-0918 liposomal doxorubicin product....
March 15, 2018
Top 10 Stem Cell Companies On The NASDAQ
The global stem cell therapy market is expected to grow at a CAGR of 36.52 percent between 2017 and 2021.... March 9, 2018
Cytori Reports Fourth Quarter and Full Year 2017 Business and Financial Results
Cytori Therapeutics (NASDAQ:CYTX) announced its fourth quarter and year-end 2017 financial results and provided updates on its corporate activity and clinical... April 10, 2017